REVIEW

A current view of serotonin transporters [version 1; peer review: 3 approved]

Louis J. De Felice

Physiology and Biophysics, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA

V1 First published: 28 Jul 2016, 5(F1000 Faculty Rev):1884
<https://doi.org/10.12688/f1000research.8384.1>
Latest published: 28 Jul 2016, 5(F1000 Faculty Rev):1884
<https://doi.org/10.12688/f1000research.8384.1>

Abstract

Serotonin transporters (SERTs) are largely recognized for one aspect of their function—to transport serotonin back into the presynaptic terminal after its release. Another aspect of their function, however, may be to generate currents large enough to have physiological consequences. The standard model for electrogenic transport is the alternating access model, in which serotonin is transported with a fixed ratio of co-transported ions resulting in net charge per cycle. The alternating access model, however, cannot account for all the observed currents through SERT or other monoamine transporters. Furthermore, SERT agonists like ecstasy or antagonists like fluoxetine generate or suppress currents that the standard model cannot support. Here we survey evidence for a channel mode of transport in which transmitters and ions move through a pore. Available structures for dopamine and serotonin transporters, however, provide no evidence for a pore conformation, raising questions of whether the proposed channel mode actually exists or whether the structural data are perhaps missing a transient open state.

Keywords

5-HT, alternating access model, SLC6, electrogenic transport, Serotonin transporters

Open Peer Review

Approval Status

	1	2	3
version 1 28 Jul 2016			

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Henry A. Lester**, California Institute of Technology, Pasadena, USA
2. **Michele Mazzanti**, University of Milano, Milano, Italy
3. **Satinder K. Singh**, Yale University School of Medicine, New Haven, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Louis J. De Felice (ljdefelice@vcu.edu)

Competing interests: The author declares that he has no competing interests.

Grant information: This work was supported by the National Institutes of Health (NIH) grant no. R01DA033930.

Copyright: © 2016 De Felice LJ. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: De Felice LJ. **A current view of serotonin transporters [version 1; peer review: 3 approved]** F1000Research 2016, 5(F1000 Faculty Rev):1884 <https://doi.org/10.12688/f1000research.8384.1>

First published: 28 Jul 2016, 5(F1000 Faculty Rev):1884 <https://doi.org/10.12688/f1000research.8384.1>

What happens when 5-hydroxytryptamine (5-HT) and therapeutic or abused drugs interact with the serotonin transporter? In addition to pharmacokinetics, drug metabolism, and the complexities of the serotonergic system, the events occurring directly at the serotonin transporter (SERT) will help us understand how therapeutic and abused drugs work. Neurotransmitter transporters and their role in synaptic transmission are broad subjects, and many topics, including the important role of 5-HT in the enteric nervous system, are not covered here. Previous reviews include^{1–10}. This commentary focuses on the transporter and small molecules (neurotransmitters and drugs) that interact with the transporter. Our discussion inevitably involves the function of SERT in heterologous expression systems, other transporters like the dopamine transporter (DAT), and currently available structural data on the solute carrier 6 (SLC6) family of neurotransmitter transporters, of which both SERT and DAT are members. This commentary also broaches the concept of channel activity in SERT, as this property is one of the most controversial but least well understood.

Biochemical characterization of SERT began in 1977, when Gary Rudnick used plasma membrane vesicles from human platelets containing human SERT (hSERT)¹¹ to study Na⁺ and Cl[−] coupled 5-HT transport. Rudnick *et al.* concluded that SERT, in common with NET (norepinephrine transporter) and DAT, has an obligatory functional dependence on Na⁺ and Cl[−]: 5-HT transport cannot occur without the co-transport of one Na⁺ and one Cl[−] ion. The standard model for monoamine transporters, and SERT in particular, thus posits fixed stoichiometry of transmitter and ions, which, in the presence of ion gradients, can drive a transmitter against its own gradient^{12–22}. In one form of this model, the influx of 5-HT (a monovalent cation at physiological pH) with Na⁺ and Cl[−] is coupled to the efflux of one K⁺ ion, thus rendering SERT electroneutral²³. However, we now know that SERT is electrogenic and that 5-HT transport generates current. It is critical to understand the molecular basis of these currents because they figure prominently in the action of antidepressants and drugs of abuse^{22,24–29}.

Two models have been proposed to explain the intriguing phenomenon of ion currents, neither of which is mutually exclusive. One model incorporates both uptake and current in one kinetic scheme³⁰, and so in this sense these two events are coupled. Another model attributes current to fixed stoichiometry, electrogenic alternating access transport with the ‘uncoupled’ current perhaps being caused by an occasional ‘slip’ into a channel mode. Such a phenomenon may occur in *Drosophila* SERT (dSERT)³¹, which exhibits remarkably high currents, with 50 charges per 5-HT (at −80 mV) versus 5–12 charges for its mammalian counterparts³². In dSERT, one of the putative extracellular gating residues is apolar asparagine instead of an acidic glutamate, as in hSERT, and thus presumably would be able to form only a hydrogen bond rather than a stronger salt bridge with its positively charged (arginine) gating partner. Regardless of the model invoked to explain transporter currents, the role of these currents at the serotonergic synapse remains unclear.

An important experiment potentially related to this question was performed by Dieter Bruns *et al.*, who used an *in vivo* preparation: the giant serotonergic synapse of the medicinal leech³³. This

work measured pre- and postsynaptic currents in response to timed presynaptic 5-HT release. Distinguishing between presynaptic versus postsynaptic events as well as transporter versus receptor current was achieved by specific, targeted placement of recording electrodes and well-established pharmacological intervention. Interestingly, the postsynaptic ionotropic 5-HT₃ receptor generated current *after* the presynaptic current associated with 5-HT transport back into the presynaptic terminal. Only a brief delay occurred between a presynaptic Ca²⁺ flash, release of 5-HT, and a presynaptic SERT current that was earlier than, but comparable in size to, the post-synaptic, 5-HT₃-gated receptor current. It would seem impossible for traditional models to explain such large SERT currents, and these data suggest that a channel may exist within SERT, although no structural evidence yet exists for such a channel.

A recent study³⁴ provided the first structural glimpse into hSERT, but only structures of a transport-deficient variant, dubbed “TS3”, in complex with two inhibitors, are described. The resolution of the transport-competent variant, dubbed “TS2”, is low (~4.5 Å) with no 5-HT, inhibitor or ions present in the electron density and consequently none in the deposited coordinate file. Higher-resolution structural studies coupled with sophisticated biophysical experiments of a transport-competent SERT in multiple conformations will be required to visualize a channel if one exists. Nevertheless, such a channel-like state may be transient and thus still be challenging to capture unless stabilized in some way. Note that existing crystal structures of homologous transporters, such as the bacterial SLC6 orthologue LeuT, which is widely used to model plasma membrane monoamine transporters, along with recent structures of *Drosophila* DAT (dDAT), provide evidence for the fixed stoichiometry, alternating access model, with no hint of a channel^{35–38}. However, the absence of such a conformation does not disprove its existence. Indeed, the proteins used for crystallization either do not exhibit channel activity (LeuT) or are highly thermostabilized, transport-deficient/impaired mutants (hSERT and dDAT) that may simply be incapable of sampling the channel-like state present in the wild-type proteins.

Unlike the biogenic amine transporters, glutamate transporters, which belong to a functionally and structurally distinct neurotransmitter transporter family (SLC1), have been known for decades to embody an authentic Cl[−] channel and thus operate normally as both a glutamate carrier and a Cl[−] ion channel^{39–45}. Is there any structural evidence for a channel in this family? Structural breakthroughs within the SLC1 family have emerged from work on an archaeal glutamate transporter homolog from *Pyrococcus horikoshii*, known as Glt_{ph}⁴⁶. Importantly, Glt_{ph} has a bona-fide Cl[−] channel⁴⁷, akin to its eukaryotic counterparts. In the crystal structure of a crosslinked Glt_{ph} mutant (Glt_{ph}-V198C-A380C) with bound mercury, one of the protomers of the asymmetric trimer serendipitously assumes an intermediate outward-facing state in which a small cavity between the transport and trimerization domains appears to be accessible from both sides of the membrane. Although this conformation may be stabilized by crystal packing, as the authors remark, the structure offers a tantalizing molecular glimpse into a plausible channel-like state⁴⁸. By contrast, as mentioned above, none of the SLC6 structures solved to date reveals such an open pathway.

If a channel exists within SLC6 members, do currents that carry Na^+ or Cl^- ions share a pathway with 5-HT? In 2011, Henry *et al.* studied the effect of an asparagine-to-alanine mutation at position 101 in TM1 of hSERT⁴⁹, which, according to LeuT-based homology models and the recent hSERT structure, resides within the transport permeation pathway, close to the putative 5-HT and ion-binding sites. Henry *et al.* found that the N101A mutation eliminated Cl^- dependence of 5-HT transport, 5-HT-induced currents, and 5-HT-independent leak currents. In fact, the N101A mutant evoked a much greater 5-HT/charge flux ratio (relative to that found in the wild-type) despite its reduced surface expression. These data suggest that N101 likely determines both Na^+ -coupled transport and channel pathways.

We also know that SERT and DAT have distinct functional states^{50–52}, and although these may reflect distinct structural pathways, there is no proof of this. However, we must conclude that perfectly coupled, fixed stoichiometric models are incomplete, if for no other reason than the existence of leak currents⁵³. Furthermore, 5-HT-induced macroscopic currents are 100 to 1,000 times larger than can be explained by a fixed stoichiometry, alternating access model, and this is another indirect argument for the existence of a channel-like pathway in SERT⁴.

Theories of transport based on flux coupling (also called frictional models) can account for observed macroscopic currents and are consistent with the existence of single transporter events^{4,31,33,54–59}. Then how is it possible that present structural data of plasma membrane monoamine transporters provide no evidence for the existence of current-generating ion pathways? Perhaps channel states in this class of transporters are unstable, simply resistant to structural analysis, especially (as mentioned above) with the thermostabilized constructs normally required to grow diffraction-quality crystals, or perhaps they need to be crystallized within a membrane-like environment, as would occur in the lipidic cubic phase⁶⁰ of phospholipid bilayer nanodiscs. Perhaps both a

current-generating construct combined with a lipidic milieu are necessary and, though entirely speculative, may need to be partnered with a presynaptic regulatory protein as would actually occur in the cell. Regardless, without structural evidence for channels in plasma membrane monoamine transporters, the existing functional data will lie dormant.

Let us return to the original question: What happens when 5-HT, therapeutic drugs, or abused drugs arrive at the serotonin transporter? As 5-HT is transported, SERT generates large depolarizing currents that are incompatible with fixed stoichiometry models but consistent with channel models^{4,27,31,61}. For drugs of abuse, consider as an example that ecstasy generates larger currents through SERT than 5-HT does. The resulting depolarization due to these currents is sufficient to open voltage-gated Ca^{++} channels²⁹. The influx of Ca^{++} could itself have effects, but certainly the resulting depolarization in serotonergic neurons would increase excitability and presynaptic 5-HT release. On the other hand, when uptake inhibitors interact with hSERT, in addition to blocking uptake they also block the inherent transporter leak current and that would hyperpolarize serotonergic neurons and decrease the probability of 5-HT release. These few examples suggest a larger picture of how transporter agonists and antagonists may influence the function of SERT in neurons given the channel-like properties of SERT. In conclusion, SERT is not only a 5-HT carrier but also may transiently act as an ion channel poised for pharmacological manipulation.

Competing interests

The author declares that he has no competing interests.

Grant information

This work was supported by the National Institutes of Health (NIH) grant no. R01DA033930.

References

- Amara SG: **Neurotransmitter transporters: new insights into structure, function and pharmacology**. *Rev Bras Biol*. 1996; **56**(Su 1 Pt 1): 5–19.
[PubMed Abstract](#)
- Blakely RD, DeFelice LJ: **All aglow about presynaptic receptor regulation of neurotransmitter transporters**. *Mol Pharmacol*. 2007; **71**(5): 1206–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bröer S, Gether U: **The solute carrier 6 family of transporters**. *Br J Pharmacol*. 2012; **167**(2): 256–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- DeFelice LJ, Goswami T: **Transporters as channels**. *Annu Rev Physiol*. 2007; **69**: 87–112.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kristensen AS, Andersen J, Jørgensen TN, *et al*: **SLC6 neurotransmitter transporters: structure, function, and regulation**. *Pharmacol Rev*. 2011; **63**(3): 585–640.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lester HA, Cao Y, Mager S: **Listening to neurotransmitter transporters**. *Neuron*. 1996; **17**(5): 807–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Naftalin RJ, De Felice LJ: **8.11 Transporters and Co-transporters in Theory and Practice**. In: *Comprehensive Biophysics*. Elsevier, 2012; **8**: 228–264.
[Publisher Full Text](#)
- Rudnick G: **Serotonin transporters—structure and function**. *J Membr Biol*. 2006; **213**(2): 101–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Sulzer D: **How addictive drugs disrupt presynaptic dopamine neurotransmission**. *Neuron*. 2011; **69**(4): 628–49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sulzer D, Galli A: **Dopamine transport currents are promoted from curiosity to physiology**. *Trends Neurosci*. 2003; **26**(4): 173–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rudnick G: **Active transport of 5-hydroxytryptamine by plasma membrane vesicles isolated from human blood platelets**. *J Biol Chem*. 1977; **252**(7): 2170–4.
[PubMed Abstract](#)
- Gu H, Caplan MJ, Rudnick G: **Cloned catecholamine transporters expressed in polarized epithelial cells: sorting, drug sensitivity, and ion-coupling stoichiometry**. *Adv Pharmacol*. 1998; **42**: 175–9.
[PubMed Abstract](#) | [Publisher Full Text](#)

13. Gu H, Wall SC, Rudnick G: **Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence.** *J Biol Chem.* 1994; **269**(10): 7124–30.
[PubMed Abstract](#)
14. Gu HH, Ahn J, Caplan MJ, *et al.*: **Cell-specific sorting of biogenic amine transporters expressed in epithelial cells.** *J Biol Chem.* 1996; **271**(30): 18100–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Gu HH, Wall S, Rudnick G: **Ion coupling stoichiometry for the norepinephrine transporter in membrane vesicles from stably transfected cells.** *J Biol Chem.* 1996; **271**(12): 6911–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Gu HH, Wu X, Giros B, *et al.*: **The NH(2)-terminus of norepinephrine transporter contains a basolateral localization signal for epithelial cells.** *Mol Biol Cell.* 2001; **12**(12): 3797–807.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Gu HH, Wu X, Han DD: **Conserved serine residues in serotonin transporter contribute to high-affinity cocaine binding.** *Biochem Biophys Res Commun.* 2006; **343**(4): 1179–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Gu XF, Azmitia EC: **Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons.** *Eur J Pharmacol.* 1993; **235**(1): 51–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Gu Y, Shrivastava IH, Amara SG, *et al.*: **Molecular simulations elucidate the substrate translocation pathway in a glutamate transporter.** *Proc Natl Acad Sci U S A.* 2009; **106**(8): 2589–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Rudnick G: **Bioenergetics of neurotransmitter transport.** *J Bioenerg Biomembr.* 1998; **30**(2): 173–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Rudnick G: **Ion-coupled neurotransmitter transport: thermodynamic vs. kinetic determinations of stoichiometry.** *Meth Enzymol.* 1998; **296**: 233–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Rudnick G, Wall SC: **The molecular mechanism of “ecstasy” [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.** *Proc Natl Acad Sci U S A.* 1992; **89**(5): 1817–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Rudnick G, Nelson PJ: **Platelet 5-hydroxytryptamine transport, an electroneutral mechanism coupled to potassium.** *Biochemistry.* 1978; **17**(22): 4739–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Baumann MH, Clark RD, Rothman RB: **Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain.** *Pharmacol Biochem Behav.* 2008; **90**(2): 208–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Cameron KN, Kolanos R, Solis E Jr, *et al.*: **Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter.** *Br J Pharmacol.* 2013; **168**(7): 1750–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Cameron K, Kolanos R, Vekariya R, *et al.*: **Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of “bath salts,” produce opposite effects at the human dopamine transporter.** *Psychopharmacology (Berl).* 2013; **227**(3): 493–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. De Felice LJ, Glennon RA, Negus SS: **Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology.** *Life Sci.* 2014; **97**(1): 20–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. F Kehr J, Ichinose F, Yoshitake S, *et al.*: **Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats.** *Br J Pharmacol.* 2011; **164**(8): 1949–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
29. Ruchala I, Cabra V, Solis E Jr, *et al.*: **Electrical coupling between the human serotonin transporter and voltage-gated Ca²⁺ channels.** *Cell Calcium.* 2014; **56**(1): 25–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. F Sandtner W, Schmid D, Schicker K, *et al.*: **A quantitative model of amphetamine action on the 5-HT transporter.** *Br J Pharmacol.* 2014; **171**(4): 1007–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
31. Petersen CI, DeFelice LJ: **Ionic interactions in the *Drosophila* serotonin transporter identify it as a serotonin channel.** *Nat Neurosci.* 1999; **2**(7): 605–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Gerstbrein K, Sitte HH: **Currents in neurotransmitter transporters.** *Handb Exp Pharmacol.* 2006; (175): 95–111.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Bruns D, Engert F, Lux HD: **A fast activating presynaptic reuptake current during serotonergic transmission in identified neurons of *Hirudo*.** *Neuron.* 1993; **10**(4): 559–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. F Coleman JA, Green EM, Gouaux E: **X-ray structures and mechanism of the human serotonin transporter.** *Nature.* 2016; **532**(7599): 334–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
35. F Krishnamurthy H, Gouaux E: **X-ray structures of LeuT in substrate-free outward-open and apo inward-open states.** *Nature.* 2012; **481**(7382): 469–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. F Wang KH, Penmatsa A, Gouaux E: **Neurotransmitter and psychostimulant recognition by the dopamine transporter.** *Nature.* 2015; **521**(7552): 322–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
37. F Singh SK, Piscitelli CL, Yamashita A, *et al.*: **A competitive inhibitor traps LeuT in an open-to-out conformation.** *Science.* 2008; **322**(5908): 1655–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
38. F Yamashita A, Singh SK, Kawate T, *et al.*: **Crystal structure of a bacterial homologue of Na⁺/Cl⁻-dependent neurotransmitter transporters.** *Nature.* 2005; **437**(7056): 215–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
39. Arriza JL, Fairman WA, Wadiche JI, *et al.*: **Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex.** *J Neurosci.* 1994; **14**(9): 5559–69.
[PubMed Abstract](#)
40. Fairman WA, Vandenberg RJ, Arriza JL, *et al.*: **An excitatory amino-acid transporter with properties of a ligand-gated chloride channel.** *Nature.* 1995; **375**(6532): 599–603.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Kavanaugh MP, Arriza JL, North RA, *et al.*: **Electrogenic uptake of gamma-aminobutyric acid by a cloned transporter expressed in *Xenopus* oocytes.** *J Biol Chem.* 1992; **267**(31): 22007–9.
[PubMed Abstract](#)
42. Larsson HP, Picard SA, Werblin FS, *et al.*: **Noise analysis of the glutamate-activated current in photoreceptors.** *Biophys J.* 1996; **70**(2): 733–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Vandenberg RJ, Arriza JL, Amara SG, *et al.*: **Constitutive ion fluxes and substrate binding domains of human glutamate transporters.** *J Biol Chem.* 1995; **270**(30): 17668–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Wadiche JI, Amara SG, Kavanaugh MP: **Ion fluxes associated with excitatory amino acid transport.** *Neuron.* 1995; **15**(5): 721–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Wadiche JI, Arriza JL, Amara SG, *et al.*: **Kinetics of a human glutamate transporter.** *Neuron.* 1995; **14**(5): 1019–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Yernool D, Boudker O, Jin Y, *et al.*: **Structure of a glutamate transporter homologue from *Pyrococcus horikoshii*.** *Nature.* 2004; **431**(7010): 811–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Ryan RM, Mindell JA: **The uncoupled chloride conductance of a bacterial glutamate transporter homolog.** *Nat Struct Mol Biol.* 2007; **14**(5): 365–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. F Verdon G, Boudker O: **Crystal structure of an asymmetric trimer of a bacterial glutamate transporter homolog.** *Nat Struct Mol Biol.* 2012; **19**(3): 355–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
49. Henry LK, Iwamoto H, Field JR, *et al.*: **A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloride-coupled neurotransmitter transport.** *J Biol Chem.* 2011; **286**(35): 30823–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Mager S, Min C, Henry DJ, *et al.*: **Conducting states of a mammalian serotonin transporter.** *Neuron.* 1994; **12**(4): 845–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. F Rodriguez-Menchaca AA, Solis E Jr, Cameron K, *et al.*: **S(+)-amphetamine induces a persistent leak in the human dopamine transporter: molecular stent hypothesis.** *Br J Pharmacol.* 2012; **165**(8): 2749–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
52. F Quick MW: **Regulating the conducting states of a mammalian serotonin transporter.** *Neuron.* 2003; **40**(3): 537–49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
53. Sonders MS, Zhu SJ, Zahniser NR, *et al.*: **Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants.** *J Neurosci.* 1997; **17**(3): 960–74.
[PubMed Abstract](#)
54. Adams SV, DeFelice LJ: **Flux coupling in the human serotonin transporter.** *Biophys J.* 2002; **83**(6): 3268–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Adams SV, DeFelice LJ: **Ionic currents in the human serotonin transporter reveal inconsistencies in the alternating access hypothesis.** *Biophys J.* 2003; **85**(3): 1548–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Carvelli L, McDonald PW, Blakely RD, *et al.*: **Dopamine transporters depolarize neurons by a channel mechanism.** *Proc Natl Acad Sci U S A.* 2004; **101**(45): 16046–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Galli A, Blakely RD, DeFelice LJ: **Patch-clamp and amperometric recordings from norepinephrine transporters: channel activity and voltage-dependent uptake.** *Proc Natl Acad Sci U S A.* 1998; **95**(22): 13260–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

58. Lin F, Lester HA, Mager S: **Single-channel currents produced by the serotonin transporter and analysis of a mutation affecting ion permeation.** *Biophys J.* 1996; **71**(6): 3126–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Su A, Mager S, Mayo SL, *et al.*: **A multi-substrate single-file model for ion-coupled transporters.** *Biophys J.* 1996; **70**(2): 762–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Cherezov V: **Lipidic cubic phase technologies for membrane protein structural studies.** *Curr Opin Struct Biol.* 2011; **21**(4): 559–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
61. Ramsey IS, DeFelice LJ: **Serotonin transporter function and pharmacology are sensitive to expression level: evidence for an endogenous regulatory factor.** *J Biol Chem.* 2002; **277**(17): 14475–82.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Satinder K. Singh**

Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA

Competing Interests: No competing interests were disclosed.

2. **Michele Mazzanti**

Department of Biosciences, University of Milano, Milano, Italy

Competing Interests: No competing interests were disclosed.

3. **Henry A. Lester**

Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research